Moderna Inc (MRNA)

[axelvento]

And this nightmare will never end:

Bancel says that Moderna is continuing to charge forward with creating new mRNA vaccines and therapies. “In 2021 and 2022 Moderna is going to scale at a pace that has never happened before in biotech,” Bancel says. From new vaccines for infectious disease to new cancer treatments$$$$$$$$

the sky is the limit!


Moderna has two cancer vaccines that use mRNA to express tumor neoantigens intended to elicit an immune response. The personalized cancer vaccine, mRNA-4157, is made by sampling a patient’s tumor and sequencing it to identify the neoantigens. The company then designs the patient’s vaccine, which has mRNA that will encode up to 34 of those neoantigens. The other cancer vaccine, mRNA-5671, addresses the four most common KRAS mutations across cancers. Mutations in the KRAS gene are found in about 22% of cancers including colorectal, non-small cell lung and pancreatic cancers.

Both of Moderna’s mRNA cancer vaccines are being developed in partnership with Kenilworth, New Jersey-based Merck. The personalized vaccine is in Phase 2 testing in combination with the pharma giant’s cancer immunotherapy Keytruda. The KRAS-targeting vaccine is in Phase 1 testing evaluating by itself and in combination with the Merck immunotherapy.


mRNA-2752#Estimated Study Completion Date:July 31, 2021

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade


https://medcitynews.com/2021/08/can-mrna-vaccines-do-for-cancer-what-they-did-with-covid-19/